🇺🇸 FDA
Pipeline program

20 µg recombinant hepatitis B vaccine at months 0, 1, and 6

2018ZX10721202001002001

Approved mab active

Quick answer

20 µg recombinant hepatitis B vaccine at months 0, 1, and 6 for Hepatitis B Vaccine is a Approved program (mab) at China SXT Pharmaceuticals with 3 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Hepatitis B Vaccine
Phase
Approved
Modality
mab
Status
active

Clinical trials